profit from every $100 of sales.
$0$100
Cibus
$1.13+3.67% today
-9.6% in 1 year
1-year low $1.091-year high $4.05
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Cibus sold, what it kept, and what it did with the cash.
Sales went from $157,000 in 2022 to $3.64 million in 2025, with -$127 million of profit last year.
SalesProfit
Cibus vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cibus | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Cibus's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 2 | 4 | 4 | |
| 0 | 2 | 4 | 4 | |
| -22 | -69 | -77 | -67 | |
| -15 | -314 | -242 | -91 | |
| -17 | -268 | -251 | -127 | |
| -18.50 | -25.95 | -10.83 | -2.78 | |
| 100.0% | 100.0% | 100.0% | 100.0% | |
| -14,248.4% | -3,823.0% | -1,805.8% | -1,853.9% | |
| -10,758.6% | -14,729.1% | -5,898.4% | -3,492.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 22 | 544 | 350 | 305 |
| Cash | 3 | 33 | 14 | 10 |
| Total debt | 14 | 25 | 36 | 33 |
| Total liabilities | 15 | 206 | 252 | 283 |
| 7 | 293 | 92 | 22 | |
| 1 | 10 | 23 | 46 | |
| -62.8% | -79.2% | -152.8% | -139.2% | |
| -233.5% | -91.2% | -272.8% | -582.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -46 | -58 | -51 | |
| 2 | 4 | 1 | 1 | |
| -21 | -51 | -59 | -51 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 16 | 11 | 8 |
Valuation
- –
- –
- –
- 30.2×
- 23.8×
- –
- –
- -59.1%
- -146.7%
- 0.0%
Profitability
- 100.0%
- -1,853.9%
- -3,492.3%
- -1,691.2%
- -30.3%
- -99.0%
- -236.8%
- -41.7%
- -30.7%
- 1,214.6%
Growth
- +185.1%
- –
- +13.1%
- –
- −5.7%
Financial health
- –
- 12.28
- 87.8%
- -2.5×
- 0.72
- 0.72
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 16%of 946
Top 2%of 867
Bottom 1%of 986
What analysts expect
- Average price target
- $11.50
- Range
- $10.50 – $12.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.33 | -0.27 | −22.2% |
| Mar 17, 2026 | -0.42 | -0.43 | +2.3% |
| Nov 13, 2025 | -0.44 | -0.41 | −7.3% |
| Aug 14, 2025 | -0.61 | -0.69 | +11.6% |
| May 8, 2025 | -0.74 | -0.70 | −5.7% |
| Mar 20, 2025 | -0.87 | -0.68 | −27.9% |
| Nov 7, 2024 | 0.06 | -0.90 | +106.7% |
| Aug 8, 2024 | -1.14 | -0.81 | −40.7% |
News
Cibus targets biofragrance peak revenue up to $100M while aiming for rice launch as early as 2028Seeking Alpha · Nov 13, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
4No pass
Philip Fisher
57No pass
Peter Lynch
40No pass
Joel Greenblatt
2No pass
Charlie Munger
41No pass
Terry Smith
38No pass
Questions about Cibus
Is Cibus a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cibus AI analysis
What does Cibus do?
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. It is in Biotechnology.
Does Cibus pay a dividend?
No. Cibus does not pay a dividend at the moment.
Is Cibus stock halal?
No. Cibus does not pass our halal screen: its debt is 38% of its market value, at or above the 33% limit. How we check
How has Cibus stock done over the past year?
Down 9.6% over the past twelve months, to $1.13. It traded between $1.09 and $4.05 and is 72.1% below its high.
Who are Cibus's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Cibus's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.